Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays
Abstract Background Activated coagulation factor XIa (FXIa) is an impurity and primary source of procoagulant activity in thrombosis‐implicated immune globulin (IG) products. Several assays, of varying quality and precision are used to assess FXIa‐like procoagulant activity in units relevant to thei...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-01-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rth2.12467 |
| _version_ | 1797765151759269888 |
|---|---|
| author | Yideng Liang Joseph W. Jackson Samuel A. Woodle Stepan S. Surov Leonid A. Parunov Dorothy E. Scott Mark Weinstein Timothy K. Lee Mikhail V. Ovanesov |
| author_facet | Yideng Liang Joseph W. Jackson Samuel A. Woodle Stepan S. Surov Leonid A. Parunov Dorothy E. Scott Mark Weinstein Timothy K. Lee Mikhail V. Ovanesov |
| author_sort | Yideng Liang |
| collection | DOAJ |
| description | Abstract Background Activated coagulation factor XIa (FXIa) is an impurity and primary source of procoagulant activity in thrombosis‐implicated immune globulin (IG) products. Several assays, of varying quality and precision are used to assess FXIa‐like procoagulant activity in units relevant to their respective principles. Objectives To advance unified reporting, we sought to employ the World Health Organization reference reagents (RRs) to present the results of differing methodologies in units of FXIa activity and rank the sensitivity and robustness of these methodologies. Methods RR 11/236 served as a calibrator in several FXIa‐sensitive blood coagulation tests: two commercial chromogenic FXIa assays (CAs); a nonactivated partial thromboplastin time (NaPTT); an in‐house fibrin generation (FG) assay; an in‐house thrombin generation (TG) assay; and an assay for FXIa‐ and kallikrein‐like proteolytic activities based on cleavage of substrate SN13a. Some assays were tested in either normal or FXI‐deficient plasma. Results Each method demonstrated a sigmoidal dose‐response to RRs. NaPTT was the least sensitive to FXIa and the least precise; our in‐house TG was the most sensitive; and the two CAs were the most precise. All methods, except for SN13a, which is less specific for thrombotic impurities, gave comparable (within 20% difference) FXIa activity assignments for IG lots. Conclusions Purified FXIa reference standards support quantitation of FXIa levels in IG products in all tested assay methodologies. This should help to standardize the measurement of thrombotic potentials in IG products and prevent products exhibiting high procoagulant activity from distribution for patient use. Further research is needed to address the effect of IG product‐specific matrixes on assay performance. |
| first_indexed | 2024-03-12T20:06:59Z |
| format | Article |
| id | doaj.art-ab2eec995bec476b91c3b022656c3222 |
| institution | Directory Open Access Journal |
| issn | 2475-0379 |
| language | English |
| last_indexed | 2024-03-12T20:06:59Z |
| publishDate | 2021-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Research and Practice in Thrombosis and Haemostasis |
| spelling | doaj.art-ab2eec995bec476b91c3b022656c32222023-08-02T02:03:22ZengElsevierResearch and Practice in Thrombosis and Haemostasis2475-03792021-01-015121122210.1002/rth2.12467Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assaysYideng Liang0Joseph W. Jackson1Samuel A. Woodle2Stepan S. Surov3Leonid A. Parunov4Dorothy E. Scott5Mark Weinstein6Timothy K. Lee7Mikhail V. Ovanesov8Center for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring MD USACenter for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring MD USACenter for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring MD USACenter for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring MD USACenter for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring MD USACenter for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring MD USACenter for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring MD USACenter for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring MD USACenter for Biologics Evaluation and Research U.S. Food and Drug Administration Silver Spring MD USAAbstract Background Activated coagulation factor XIa (FXIa) is an impurity and primary source of procoagulant activity in thrombosis‐implicated immune globulin (IG) products. Several assays, of varying quality and precision are used to assess FXIa‐like procoagulant activity in units relevant to their respective principles. Objectives To advance unified reporting, we sought to employ the World Health Organization reference reagents (RRs) to present the results of differing methodologies in units of FXIa activity and rank the sensitivity and robustness of these methodologies. Methods RR 11/236 served as a calibrator in several FXIa‐sensitive blood coagulation tests: two commercial chromogenic FXIa assays (CAs); a nonactivated partial thromboplastin time (NaPTT); an in‐house fibrin generation (FG) assay; an in‐house thrombin generation (TG) assay; and an assay for FXIa‐ and kallikrein‐like proteolytic activities based on cleavage of substrate SN13a. Some assays were tested in either normal or FXI‐deficient plasma. Results Each method demonstrated a sigmoidal dose‐response to RRs. NaPTT was the least sensitive to FXIa and the least precise; our in‐house TG was the most sensitive; and the two CAs were the most precise. All methods, except for SN13a, which is less specific for thrombotic impurities, gave comparable (within 20% difference) FXIa activity assignments for IG lots. Conclusions Purified FXIa reference standards support quantitation of FXIa levels in IG products in all tested assay methodologies. This should help to standardize the measurement of thrombotic potentials in IG products and prevent products exhibiting high procoagulant activity from distribution for patient use. Further research is needed to address the effect of IG product‐specific matrixes on assay performance.https://doi.org/10.1002/rth2.12467blood coagulation testscalibrationcoagulation factor XIaimmune globulinthrombin |
| spellingShingle | Yideng Liang Joseph W. Jackson Samuel A. Woodle Stepan S. Surov Leonid A. Parunov Dorothy E. Scott Mark Weinstein Timothy K. Lee Mikhail V. Ovanesov Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays Research and Practice in Thrombosis and Haemostasis blood coagulation tests calibration coagulation factor XIa immune globulin thrombin |
| title | Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays |
| title_full | Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays |
| title_fullStr | Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays |
| title_full_unstemmed | Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays |
| title_short | Detecting factor XIa in immune globulin products: Commutability of international reference materials for traditional and global hemostasis assays |
| title_sort | detecting factor xia in immune globulin products commutability of international reference materials for traditional and global hemostasis assays |
| topic | blood coagulation tests calibration coagulation factor XIa immune globulin thrombin |
| url | https://doi.org/10.1002/rth2.12467 |
| work_keys_str_mv | AT yidengliang detectingfactorxiainimmuneglobulinproductscommutabilityofinternationalreferencematerialsfortraditionalandglobalhemostasisassays AT josephwjackson detectingfactorxiainimmuneglobulinproductscommutabilityofinternationalreferencematerialsfortraditionalandglobalhemostasisassays AT samuelawoodle detectingfactorxiainimmuneglobulinproductscommutabilityofinternationalreferencematerialsfortraditionalandglobalhemostasisassays AT stepanssurov detectingfactorxiainimmuneglobulinproductscommutabilityofinternationalreferencematerialsfortraditionalandglobalhemostasisassays AT leonidaparunov detectingfactorxiainimmuneglobulinproductscommutabilityofinternationalreferencematerialsfortraditionalandglobalhemostasisassays AT dorothyescott detectingfactorxiainimmuneglobulinproductscommutabilityofinternationalreferencematerialsfortraditionalandglobalhemostasisassays AT markweinstein detectingfactorxiainimmuneglobulinproductscommutabilityofinternationalreferencematerialsfortraditionalandglobalhemostasisassays AT timothyklee detectingfactorxiainimmuneglobulinproductscommutabilityofinternationalreferencematerialsfortraditionalandglobalhemostasisassays AT mikhailvovanesov detectingfactorxiainimmuneglobulinproductscommutabilityofinternationalreferencematerialsfortraditionalandglobalhemostasisassays |